Search clinical trials for: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T

Total 1712 results

Adaptimmune

Completed

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Carcinoma | Non-Small Cell Lung Cancer

United States, Spain, United Kingdom, Canada
Adaptimmune

Active, not recruiting

AFPᶜ³³²T in Advanced HCC

Hepatocellular Cancer | AFP Expressing Tumors

United States, United Kingdom, France, Spain
Adaptimmune

Terminated

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Melanoma

United States
Adaptimmune

Completed

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Melanoma | Head and Neck Cancer | Urothelial Carcinoma | Bladder Urothelial Carcinoma

United States, Canada, Spain
In8bio Inc.

Recruiting

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Glioblastoma

United States
Adaptimmune

Active, not recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Melanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell Liposarcoma

United States, Canada
GlaxoSmithKline

Completed

Redirected Auto T Cells for Advanced Myeloma

Multiple Myeloma

United States
University of Cologne

Unknown

Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides (TECLA)

CD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis Fungoides

Germany
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
University of Pennsylvania

Completed

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy (MazF)

HIV

United States
VIRxSYS Corporation

Active, not recruiting

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

HIV Infection

United States
Nanfang Hospital of Southern Medical University
Guangdong Yike Gene Science and Technology CO.,Ltd

Unknown

Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified

Beta Thalassemia Major

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 (CART-138)

Multiple Myeloma

China
Sun Yat-sen University
Guangzhou Bio-gene Technology Co., Ltd.

Unknown

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

Non Small Cell Lung Cancer

China
Changhai Hospital

Recruiting

A Study of IMC008 for Advanced Solid Tumors

Advanced Solid Tumor

China
Adaptimmune

Terminated

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Solid and Hematological Malignancies

United States, Canada
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Roger Williams Medical Center

Suspended

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Metastatic Cancers

United States
Roger Williams Medical Center

Terminated

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Colorectal Cancer

United States
University of Pennsylvania

Completed

Autologous Redirected RNA Meso-CIR T Cells

Malignant Pleural Mesothelioma

United States
University College, London

Completed

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation (CARD)

CD19+ Malignancies: Relapse Post-allogeneic Transplant

United Kingdom
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
The First Affiliated Hospital of Nanchang University

Unknown

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
University of Florida
United States Department of Defense; AM Rosen Foundation

Recruiting

Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT)

Glioblastoma | Glioblastoma Multiforme

United States
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
The Nordic Network For Clinical Islet Transplantation

Active, not recruiting

Infusion of Autologous T Regulatory Cells (T Reg) at the Time of Transplantation of Allogenic Islets of Langerhans

Type1diabetes

Sweden
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
University of Pennsylvania

Completed

Autologous CD4 T-Cells in HIV (C34-CXCR4)

Hiv

United States
Adaptimmune
ICON plc

Terminated

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Esophageal Cancer | Esophagogastric Junction Cancer

United States, Canada, Spain
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Recurrent Mantle Cell Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Refractory Chronic Lymphocytic Leukemia | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Acute Lymphoblastic Leukemia | Metastatic Triple-Negative... and other conditions

United States
University of Cincinnati
University of California, San Francisco; Case Western Reserve University

Active, not recruiting

CCR5-modified CD4+ T Cells for HIV Infection (TRAILBLAZER)

HIV Infections

United States
National Center for Tumor Diseases, Heidelberg
German Cancer Research Center; University Hospital Heidelberg

Terminated

Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer (ATACC)

Colorectal Carcinoma

Germany
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Malignant Glioma of Brain | Gastric Carcinoma | Colorectal Carcinoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
King's College Hospital NHS Trust

Recruiting

Autologous Tregs for Aplastic Anaemia (TIARA)

Aplastic Anemia

United Kingdom
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Sara V. Latorre
Instituto de Salud Carlos III

Completed

Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy (CART19-BE-01)

Lymphoma | Leukemia

Spain
Rapa Therapeutics LLC
Massachusetts General Hospital; Hackensack Meridian Health

Available

RAPA-501 Therapy for ALS EAP

Amyotrophic Lateral Sclerosis

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Active, not recruiting

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China

Search clinical trials for: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations